



Medicines & Healthcare products Regulatory Agency

MHRA Central Freedom of
Information Team
10 South Colonnade
Canary Wharf
London
E14 4PU

foi.request@mhra.gov.uk.

[MHRA Website](https://www.mhra.gov.uk)

Our Ref: **FOI2026/00653**

16 July 2026

Dear [REDACTED]

Thank you for your Freedom of Information (FOI) request received on 18 June 2026. You wrote:

*Please can you kindly provide the finished product manufacturer(s) name(s) and address(s) as well as the Active Substance Manufacturer(s) details for:
Ixazomib 2.5 mg, 3 mg and 4 mg hard capsules
(previously called Ninlaro hard capsules)
MA numbers: PLGB 15475/0059, PLGB 15475/0060 and PLGB 15475/0061
MAH: Takeda Pharma A/S, Delta Park 45, 2665 Vallensbaek Strand,
Denmark*

MHRA Response

We confirm that we hold the information you have requested. However, the information you have requested is commercially sensitive and is, therefore, exempt from release under Section 41(1), and Section 43(1)/Section 43(2) of the FOI Act.

We will explain these exemptions below.

Section 41:

(1) Information is exempt information if — (a) it was obtained by the public authority from any other person (including another public authority), and, (b) the disclosure of the information to the public (otherwise than under this Act) by the public authority holding it would constitute a breach of confidence actionable by that or any other person.

Section 43:

- (1) Information is exempt information if it constitutes a trade secret.
- (2) Information is exempt information if its disclosure under this Act would, or would be likely to, prejudice the commercial interests of any person (including the public authority holding it).

Regarding the use of Section 41, the information you have requested relates to the finished product manufacturers and active substance manufacturers for granted marketing authorisations. This information was obtained by the Agency from the marketing authorisation holder and the Agency believes that if this information were released it would be an actionable breach of confidence. Therefore, we are not going to be releasing the requested information.

Regarding the use of Section 43, this exempts information which if disclosed would be likely to prejudice the commercial interests of any person including a public authority. It protects not only the commercial interests of third parties, but also the commercial interests of the Agency. It is intended to protect the ability of a public authority like MHRA to obtain goods or services on the best possible commercial terms and to protect the legitimate commercial interests of its suppliers. The information you seek falls into this category. In order to apply Section 43 properly, a consideration of the public interest (public interest test) is required.

Public interest test

Section 17(3) of the Act requires us to conduct a Public Interest Test (PIT) when applying of a qualified exemption. In applying this exemption, we are required to consider whether, in all the circumstances of the case, the public interest in withholding the information outweighs the public interest in releasing the information held. The 'public interest' is not the same as what interests the public. In carrying out a PIT, we consider the greater good or benefit to the community as a whole in withholding. The 'right to know' must be balanced against the need to enable effective procedural governance and to serve the best interests of the public. The FOI Act is 'applicant blind'. This means that we cannot, and do not, ask about the motives of anyone who asks for information. In providing a response to one person, we are expressing a willingness to provide the same response to anyone.

Considerations in favour of releasing the information

To release this information would benefit in general by showing transparency in MHRA's day-to-day work to the public for the public to see all sites related to the manufacture of an authorised medicine.

Considerations in favour withholding the information

Information on the manufacturing sites used by marketing authorisation holders for their products is commercially sensitive information that has been provided to MHRA in confidence. To publish this information would be to provide competitor companies with information on where this product can be sourced, helping these companies in sourcing their own product manufacturers to the commercial detriment of the marketing authorisation holder concerned (in this case Takeda Pharma A/S).

On balance we are satisfied that, in this instance, the public interest in applying the exemption outweighs the public interest in disclosure.

If you have any queries about this letter, please contact us quoting the reference number above.

Yours sincerely,

MHRA Central Freedom of Information Team
Medicines & Healthcare products Regulatory Agency

Your right to complain under the Freedom of Information Act

If you are not happy with this response you may request an internal review by e-mailing foi.request@mhra.gov.uk or by writing to: MHRA Central Freedom of Information Team, 10 South, Colonnade, Canary Wharf, London, E14 4PU

Any request for an internal review must be received by us within 40 working days of the date of this letter. Please note we are not obliged to provide a review if it is requested after more than 40 working days.

If you are not content with the outcome of the internal review, you may apply directly to the Information Commissioner's Office for a decision. Generally, the Commissioner cannot make a decision unless you have exhausted our own complaints procedure. The Information Commissioner can be contacted at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

Website: [ICO FOI and EIR complaints](#) or telephone 0303 123 1113.

Re-use of our information

The MHRA information supplied in response to your request is subject to Crown copyright. Information created by the MHRA which is disclosed under the Freedom of Information Act is made available for re-use under the Open Government Licence (OGL) v3.0, except where this is otherwise stated. There are some restrictions on re-use under the OGL and these can be viewed here:

<https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>